Fapon, a globally leading life sciences organization, will exhibit at the AMP 2025 Annual Meeting & Expo during November 11-15 in Boston, presenting its cutting-edge enzymes for molecular diagnostics ...

Both tobevibart (a monoclonal antibody) and elebsiran (a small interfering RNA) target hepatitis B virus surface antigen (HBsAg). Their efficacy and safety in the treatment of chronic hepatitis D ...

A new gene-editing technique enables the correction of multiple genetic mutations simultaneously, transforming the prospects ...

WASHINGTON -- An investigational dual therapy appeared to show antiviral activity in patients with chronic hepatitis D virus (HDV) infection, according to the phase II SOLSTICE trial.

King’s College London researchers discovered that parts of our DNA once thought to be “junk” can actually help destroy cancer ...

EDP-323 significantly reduced mean viral load AUC by 85% and 87% in the high- and low-dose groups, respectively, compared ...

Researchers discovered that bowhead whales achieve extraordinary longevity and cancer resistance through highly efficient and ...

Emerging trends in Healthcare Stocks include increasing adoption of gene therapies, advancements in precision medicine, and ...

Pluribus season 1 premiered on Apple TV on November 7, 2025. Read on to discover who stars in the show.

Gilead Sciences approaches Q3 2025 results on October 30, hitting new highs and presenting Livdelzi data at The Liver Meeting. Check out why GILD stock is a strong buy.

APPLIN: After nearly 20 years in HIV care, I’ve seen that HIV follows people through every season of life. When life is stable, patients stay in care and maintain suppression, but when challenges ...